Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sirolimus for Chronic Rejection After Lung Transplant
NCT04415476Phase 2Withdrawn
- Sponsor
- University of Maryland, Baltimore
- Start
- Jun 2020
- Primary completion
- Jun 2024
- Modality
- Small Molecules
01
Overview
Phase 2, randomised, open-label trial in chronic lung transplant rejection (CLAD) comparing Sirolimus Arm with Standard of Care Arm (2 arms). Primary endpoints: Efficacy failure (progression of BOS, re-transplantation, or death) at 96 weeks, Death at 2 years and 2 more. Planned start Jun 2020; status: withdrawn.
02
Drugs
sirolimus
03
Conditions
chronic lung transplant rejection (CLAD)
Beyond the preview
Go deeper on NCT04415476.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04415476.